Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction

• Autor(a) principal: the ARIADNE investigators
• Data de Publicação: 2022
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/144429
• topic: ARNI; Heart failure; Heart failure with reduced ejection fraction; Outcomes; Outpatients; Sacubitril/valsartan; Cardiology and Cardiovascular Medicine

Funding Information: APM reports personal fees from Novartis during the conduct of the study and personal fees from Bayer, personal fees from AstraZeneca, and personal fees from Fresenius, outside the submitted work. ALC reports personal fees and non‐financial support from Novartis during the conduct of the study. VB declares grants and personal fees from Novartis during the conduct of the study and personal fees from Astra Zeneca and Boehringer Ingelheim‐Lilly Alliance. TD reports grants and personal fees from Pfizer, grants and personal fees from Novartis, grants and personal fees from Bayer, and personal fees from Astra Zeneca, outside the submitted work. JD has nothing to disclose. CF reports personal fees from Novartis during the conduct of the study personal fees from Servier, personal fees and other from AstraZeneca, personal fees and other from Bayer, personal fees and other from Vifor Pharma, personal fees and other from Novartis, and other from Boehringer, outside the submitted work. LHL reports grants and personal fees from Novartis, during the conduct of the study; personal fees from Merck, personal fees from Sanofi, grants and personal fees from Vifor‐Fresenius, grants and personal fees from AstraZeneca, grants and personal fees from Relypsa, personal fees from Bayer, grants from Boston Scientific, personal fees from Pharmacosmos, personal fees from Abbott, grants and personal fees from Mundipharma, personal fees from Medscape, personal fees from Myokardia, and grants and personal fees from Boehringer Ingelheim, outside the submitted work. SK is an employee of GKM (clinical research organization) contracted for data analysis by Novartis and received fees from Novartis during the conduct of the study. PCF and CK are employees of Novartis. RIH was an employee of Novartis when the study was conducted. UZ reports grants and personal fees from Novartis during the conduct of the study and grants and personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, grants and personal fees from BMS, personal fees from MSD, personal fees from Sanofi, grants and personal fees from Pfizer, personal fees from Trommsdorf, personal fees from Amgen, and grants and personal fees from Bayer, outside the submitted work. Funding Information: This work was supported by Novartis Pharma AG. Publisher Copyright: © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.